Oruka Therapeutics, Inc.
ORKANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 |
| Operating income | −$122.1M | −$88.1M | −$7.3M | −$10.6M | −$19.3M | −$9.8M |
| Net income | −$105.4M | −$83.7M | −$5.3M | −$9.9M | −$19.3M | −$9.7M |
| Total assets | $488.6M | $396.0M | $37.9M | $43.1M | $54.9M | $50.4M |
| Total liabilities | $16.7M | $13.8M | $841,000 | $1.4M | $3.9M | $3.9M |
| Equity | $471.9M | $1,000 | $37.0M | $41.7M | $51.0M | $46.5M |
| EPS (diluted) | — | $-3.87 | $-0.37 | $-0.69 | $-1.39 | — |
| Shares out. | 37.4M | 14.5M | 14.4M | 14.4M | 14.4M | 1.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −22.3%
- Return on assets
- −21.6%
- Return on capital (ROCE)
- −25.8%
- Liabilities / assets
- 3.4%
- Debt / equity
- 0.04×
- Book value / share
- $12.60
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 31.16safe
- Accruals / assets
- −3.5%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-04ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
- Phase 1Active Not Recruitingreadout ~2027-01ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
- Phase 2Recruitingreadout ~2027-06Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
- Phase 2Recruitingreadout ~2027-10Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
- Phase 2Recruitingreadout ~2030-05An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Viking Global Investors LpPassive (13G)May 15, 2026
- Fairmount Funds Management LlcActivist (13D)May 4, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Rtw Investments, LpPassive (13G)Feb 17, 2026
- Deep Track Capital, LpPassive (13G)Feb 13, 2026
- Blackrock, Inc.Passive (13G)Jan 21, 2026
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)Nov 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Dambkowski CarlDirector | May 21, 2026 | Option exercise | 38,689 | $6.84 |
| Agarwal ArjunOfficer — Senior Vice President, Finance | May 18, 2026 | Option exercise | 2,000 | $12.50 |
| Goncalves JoanaOfficer — Chief Medical Officer | May 15, 2026 | Option exercise | 3,500 | $6.84 |
| Sandler Laura LeeOfficer — Chief Operating Officer | May 1, 2026 | Option exercise | 5,000 | $7.80 |
| Goncalves JoanaOfficer — Chief Medical Officer | Apr 15, 2026 | Option exercise | 3,500 | $6.84 |
| Klein Lawrence OttoOfficer — Chief Executive Officer | Mar 16, 2026 | Sell | 1,729 | $41.30 |
| Agarwal ArjunOfficer — Senior Vice President, Finance | Mar 16, 2026 | Sell | 395 | $41.30 |
| Sandler Laura LeeOfficer — Chief Operating Officer | Mar 16, 2026 | Sell | 600 | $41.30 |
| Goncalves JoanaOfficer — Chief Medical Officer | Mar 16, 2026 | Option exercise | 3,500 | $6.84 |
| Quinlan Paul TOfficer — General Counsel | Mar 16, 2026 | Sell | 733 | $41.30 |
| Sandler Laura LeeOfficer — Chief Operating Officer | Mar 2, 2026 | Option exercise | 5,000 | $7.80 |
| Goncalves JoanaOfficer — Chief Medical Officer | Feb 17, 2026 | Option exercise | 3,500 | $6.84 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.3M | 3.6 | -10.6% |
| Apr 30, 2026 | 7.0M | 2.6 | +26.3% |
| Apr 15, 2026 | 5.5M | 4.0 | +22.4% |
| Mar 31, 2026 | 4.5M | 5.0 | +24.1% |
| Mar 13, 2026 | 3.6M | 7.5 | -18.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Results of operations · Other material eventApr 30, 2026
- Regulation FD disclosure · Other material eventApr 27, 2026
- Director / officer changeDec 11, 2025
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureSep 22, 2025
- Director / officer changeJul 1, 2025
- Shareholder voteJun 3, 2025
- Entered a material agreementFeb 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KCURRENT REPORTJun 1, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 22, 2026
- 144May 21, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 18, 2026
- 144May 18, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QQUARTERLY REPORTMay 13, 2026
- SCHEDULE 13D/AMay 4, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 1, 2026
- 144May 1, 2026
- 8-KCURRENT REPORTApr 30, 2026
- 424B5PROSPECTUS SUPPLEMENTApr 29, 2026
- 424B5PRELIMINARY PROSPECTUS SUPPLEMENTApr 27, 2026
- 424B5PRELIMINARY PROSPECTUS SUPPLEMENTApr 27, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.